Лекции

Софосбувир-содержащие схемы противовирусной терапии хронического гепатита С, актуальные в Российской Федерации в 2018 г.

Скачать статью в PDF

После регистрации в Российской Федерации софосбувира (Совальди ®) особую актуальность приобрели схемы противовирусной терапии хронического гепатита С (ХГС) на основе этого препарата. В статье обсуждаются данные об эффективности четырех вариантов лечения, зарегистрированных в Российской Федерации: софосбувир + рибавирин, софосбувир + пегилированный интерферон (Пег-ИФН)-α /рибавирин, софосбувир + симепревир, софос бувир + даклатасвир. Для обоснования использования в обычной клинической практике софосбувир-содержащих схем лечения в определенных группах больных авторы использовали частоту стойкого вирусологического ответа (СВО) ≥90%, причем в обязательном порядке учитывалась расчетная условная стоимость конкретной схемы лечения в ценах 2018 г.

Полный текст статьи не опубликован.

Используемые источники

  1. Herbst DA, Reddy KR. Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. Expert Opin Investig Drugs 2013;22(4):527-36.
  2. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368(20):1878-87.
  3. Jacobson IM, Gordon SC, Kowdley KV, et al; POSITRON Study; FUSION Study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368(20):1867-77.
  4. Zeuzem S, Dusheiko GM, Salupere R, et al; VALENCE Investigators. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014;370(21):1993-2001.
  5. Sulkowski MS, Naggie S, Lalezari J, et al.; PHOTON-1 Investigators. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014; 312(4):353-61.
  6. Molina JM, Orkin C, Iser DM, et al; PHOTON-2 study team. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet 2015;385:1098-106.
  7. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368(20):1878-87.
  8. Foster GR, Pianko S, Brown A, et al; BOSON Study Group. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology 2015;149(6):1462-70.
  9. Kalal C, Shukla A, Mohanka R, et al. Sofosbuvir, Peg Interferon & Ribavirin for retreatment of HCV genotype 1b following Sofosbuvir and Ledipasvir failure. Hepatology 2017, doi: 10.1002/hep.29667 [Epub ahead of print].
  10. Raboisson P, de Kock H, Rosenquist A, et al. Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350. Bioorg Med Chem Lett 2008;18(17):4853-8.
  11. Lawitz E, Matusow G, DeJesus E, et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: Aphase 3 study (OPTIMIST-2). Hepatology 2016;64(2):360-9.
  12. Hezode C, Chevaliez S, Scoazec G, et al. Retreatment with sofosbuvir and simeprevir of patients who previously failed on an HCV NS5A inhibitor–containing regimen. AASLD 2015, Poster Session 2, Abstract 1123.
  13. Hezode C, Chevaliez S, Scoazec G, et al. Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed adaclatasvir-containing regimen. Hepatology 2016;63(6):1809-16.
  14. Herbst DA, Reddy KR. NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection. Expert Opin Investig Drugs 2013;22(10):1337-46.
  15. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al; AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370(3):211-21.
  16. Nelson DR, Cooper JN, Lalezari JP, et al; ALLY-3 Study Team. All-oral 12week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015;61(4):1127-35.
  17. Leroy V, Angus P, Bronowicki JP, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+). Hepatology 2016;63(5):1430-41.
  18. Wyles DL, Ruane PJ, Sulkowski MS, et al; ALLY-2 Investigators. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med 2015; 373(8):714-25.
  19. Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology 2016;63(5):1493-1505.
  20. Zarkua J, Zakalashvili M, Gish RG, Metreveli D. Identification of Recombinant Strains in HCV Genotype 1 and 3: Is it needed? Liver Int 2018, doi: 10.1111/liv.13729.
  21. Zakalashvili M, Zarkua J, Weizenegger M, et al. Identification of hepatitis C virus 2 k/1b intergenotypic recombinants in Georgia. Liver Int 2018;38(3):451-7.
  22. Paolucci S, Premoli M, Ludovisi S, et al. HCV intergenotype 2k/1b recombinant detected in a DAA-treated patient in Italy. Antivir Ther 2017;22(4):365-8.
  23. Kalinina O, Norder H, Mukomolov S, Magnius LO. A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg. J Virol 2002;76(8): 4034-43.
  24. De Keukeleire S, Descheemaeker P, Reynders M. Potential risk of misclassification HCV 2k/1b strains as HCV 2a/2c using VERSANT HCV Genotype 2.0 assay. Diagn Microbiol Infect Dis 2015;82(3):201-2.
  25. Kurbanov F, Tanaka Y, Chub E, et al. Molecular epidemiology and interferon susceptibility of the natural recombinant hepatitis C virus strain RF1_2k/1b. J Infect Dis 2008;198(10):1448-56.
  26. Todt D, Schlevogt B, Deterding K, et al. Successful retreatment of a patient with chronic hepatitis C genotype 2k/1b virus with ombitasvir/paritaprevir/ritonavir plus dasabuvir. J Antimicrob Chemother 2017;72(5):1541-3.
  27. Mukomolov S, Trifonova G, Levakova I, et al. Hepatitis C in the Russian Federation: challenges and future directions. Hepat Med 2016;